The Claim
In adults with type 2 diabetes, administration of liraglutide at doses of 0.6, 1.2, and 1.8 mg/day significantly increases fasting and postprandial insulin levels compared to placebo, indicating enhanced insulin secretion as the primary mechanism for glucose lowering.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes, liraglutide at doses of 0.6, 1.2, and 1.8 mg per day increases insulin levels after fasting and after meals compared to a placebo, and this increase in insulin is the main reason blood sugar levels go down.
See the scientific wording
In adults with type 2 diabetes, liraglutide at all tested doses (0.6, 1.2, and 1.8 mg/day) significantly increases both fasting and postprandial insulin levels compared to placebo, indicating enhanced insulin secretion as a primary mechanism of glucose lowering.
Liraglutide binds to receptors on insulin-producing cells in the pancreas, which triggers a chemical signal inside the cells that causes them to release more insulin when blood sugar is high. This increased insulin lowers blood glucose levels both after meals and while fasting.
What the research says
1 studyThis study found that in people with type 2 diabetes, taking liraglutide made their bodies produce more insulin both when fasting and after eating, which helps lower blood sugar. So yes, it supports the idea that liraglutide works by boosting insulin production.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.